Bio-Rad Updates Sartorius AG Financials Following 10-K Disclosure
BIO sits 29% above its 52-week low of $211.43.
Summary
Bio-Rad Laboratories provided an update on its investment in Sartorius AG, disclosing Sartorius's full-year 2025 financial results, which were recently made public.
Key Events · Earnings and Guidance · BIO
-
Discloses Sartorius AG's 2025 Financials
Bio-Rad provided an update on its investment in Sartorius AG, detailing the latter's full-year 2025 financial results, including €3,538.1 million in sales revenue and €230.4 million in net profit.
-
Follows Recent 10-K Filing
This update supplements information regarding the Sartorius AG investment that was initially disclosed in Bio-Rad's Form 10-K filed on February 13, 2026.
Analysis · BIO · Industrial Applications And Services
This 8-K provides new financial details for Bio-Rad's significant investment in Sartorius AG, supplementing information previously disclosed in Bio-Rad's 10-K filed on February 13, 2026. The update includes Sartorius AG's full-year 2025 sales revenue of €3,538.1 million and net profit of €230.4 million, offering investors a more current view of the performance of this material asset.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BIO was trading at $271.90 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $7.3B. The 52-week trading range was $211.43 to $343.12. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.